Catalog No.
Product Name
Application
Product Information
Citations
-
SMARCA2/4 PROTAC Degrader
PROTAC SMARCA2/4-degrader-27 is a PROTAC-based degrader that specifically targets the SMARCA2 and SMARCA4 proteins. This compound induces targeted protein degradation, facilitating the selective modulation of these chromatin remodelers. It is essential for research applications exploring the roles of SMARCA2 and SMARCA4 in cancer and other diseases, allowing for valuable insights into epigenetic regulation and therapeutic strategies. -
PROTAC SMARCA2 Degrader
PROTAC SMARCA2 degrader-30 is an investigative PROTAC designed for targeted degradation of SMARCA2 protein. It demonstrates potent biological activity with a DC50 of less than 100 nM in H1299 cells, making it a valuable tool for research in cancer biology and therapeutic development. This compound may facilitate studies on the role of SMARCA2 in cellular processes and its potential as a therapeutic target in oncogenic pathways. -
PROTAC BRD4 Degrader
PROTAC BRD4 Degrader-3 is a targeted protein degradation compound that operates through the recruitment of von Hippel-Lindau (VHL) ligands to promote the ubiquitination and subsequent proteasomal degradation of the BRD4 protein. This compound demonstrates significant efficacy in downregulating BRD4, a key regulator in various cancers and inflammatory diseases. Research applications for PROTAC BRD4 Degrader-3 include the investigation of therapeutic strategies for cancer treatment and exploring the role of BRD4 in gene expression and signaling pathways. -
SMARCA2/4 PROTAC Degrader
PROTAC SMARCA2/4-degrader-5 is a PROTAC degrader targeting the catalytic subunits SMARCA2 and SMARCA4 of the SWI/SNF complex. It effectively degrades SMARCA2 in MV411 and A549 cell lines with a DC50 of less than 100 nM, and targets SMARCA4 in MV411 with a DC50 ranging from 100 to 500 nM. This compound is instrumental for research applications focused on epigenetic regulation and oncogenic pathways involving SWI/SNF complex alterations. -
MLLT1 PROTAC Degrader
PROTAC MLLT1 Degrader-1 is a targeted PROTAC degrader that specifically interacts with MLLT1. This compound effectively inhibits proliferation and viability of acute myeloid leukemia (AML) cells, while also suppressing tumor growth in human AML xenograft models. PROTAC MLLT1 Degrader-1 can be utilized for research focused on MLL-rearranged AML, enabling studies on its oncogene transcriptional regulation and potential therapeutic applications. -
BRD4 PROTAC Degrader
NEP108 is a GID4 E3 ligase-based PROTAC degrader specifically targeting BRD4. With a DC50 value of approximately 3.8 μM, NEP108 demonstrates a strong affinity for GID4, exhibiting a KD value of 0.22 μM, while the KD value for its trimeric complex is 2.85 μM. This compound is suitable for research applications in cancer biology, facilitating the study of BRD4 degradation and its implications in therapeutic strategies. -
PROTAC BRD4 Degrader
PROTAC BRD4 Degrader-22 is a PROTAC-based degrader targeting the bromodomain-containing protein 4 (BRD4). This compound demonstrates significant biological activity with a pDC50 value of 9.2 in MOLT4 cells after 24 hours of treatment. It is primarily utilized in research applications focused on exploring the therapeutic potential of targeted protein degradation in various cancers and other BRD4-related disorders. -
SMARCA2/4 Degrader
PROTAC SMARCA2/4-degrader-30 is a targeted protein degradation agent specifically designed to degrade the catalytic subunits of the SWI/SNF complex, SMARCA2 and SMARCA4. This compound demonstrates effective degradation of SMARCA2 in A549 cells and SMARCA4 in MV411 cells, with a DC50 of less than 100 nM for both targets. It serves as a valuable tool for investigating the biological roles of SMARCA2 and SMARCA4 in various cancer models and for exploring potential therapeutic strategies in malignant conditions involving these proteins. -
BRD4 PROTAC Degrader
PROTAC BRD4 Degrader-35 is a PROTAC degrader specifically designed to target BRD4. This compound facilitates the ubiquitination and subsequent degradation of BRD4, making it a valuable tool in anti-cancer research. Its mechanism of action enables the modulation of BRD4-dependent pathways, providing insights into the therapeutic potential of BRD4 inhibition in various malignancies. -
SMARCA2 PROTAC Degrader
PROTAC SMARCA2/4-degrader-8 is a specialized PROTAC targeting the catalytic subunit SMARCA2 of the SWI/SNF complex. This compound effectively degrades SMARCA2 with a DC50 of less than 100 nM in A549 cells, while also targeting SMARCA4 with equivalent efficiency in MV411 cells. It serves as a valuable tool in research focused on understanding the roles of these proteins in chromatin remodeling and their implications in various cancer types. -
SMARCA2 PROTAC Degrader
PROTAC SMARCA2 degrader-5 is a potent degrader specifically designed to target the catalytic subunit SMARCA2 of the SWI/SNF chromatin remodeling complex. This compound effectively induces degradation of SMARCA2 in MV411 and A549 cell lines, demonstrating a DC50 of less than 100 nM, while also degrading SMARCA4 with a DC50 between 100-500 nM. This reagent is essential for researchers investigating the functional role of SMARCA2 and its associated pathways in cancer biology and other cellular processes. -
PROTAC BRD9 Degrader
(S,R)-CFT8634 is a selective PROTAC-class degrader targeting BRD9, designed for oral administration. This compound facilitates the ubiquitination and subsequent degradation of BRD9, which is implicated in various diseases characterized by abnormal cell proliferation. The structure comprises a BRD9 ligand, a CRBN ligase ligand, and a PROTAC linker, enabling effective recruitment of the E3 ligase for degradation. (S,R)-CFT8634 is a valuable tool for investigating BRD9-related biological processes and therapeutic strategies. -
Ligands for Target Protein for PROTAC Chemical
PROTAC BRD4 ligand-2 is a specific ligand for the BRD4 protein, designed for use in PROTAC-mediated degradation strategies. This compound facilitates the targeted degradation of BRD4, a key regulator of transcription and associated with various cancers, by recruiting the E3 ubiquitin ligase. It is instrumental in research applications aimed at understanding BRD4's role in oncogenesis and therapeutic development in cancer treatments. -
BRD4 PROTAC Degrader
PROTAC BRD4 Degrader-34 is a selective degrader that targets the bromodomain-containing protein 4 (BRD4) through a proteolysis-targeting chimera (PROTAC) mechanism. It induces the degradation of the BRD4-BD2 domain via the VHL E3 ubiquitin ligase system. This compound has significant potential for use in cancer research, enabling investigations into the therapeutic effects of targeting BRD4 in oncogenic pathways. -
SMARCA2/4 PROTAC degrader
PROTAC SMARCA2/4 degrader-37 is a proteolysis-targeting chimera (PROTAC) that selectively degrades SMARCA2 and SMARCA4 proteins. It exhibits a potent inhibitory concentration (IC50) of ≤0.1 μM, highlighting its efficacy in disrupting these bromodomain-containing proteins. This reagent is suitable for applications in cancer research and therapeutic development, particularly in studies involving epigenetic modulation and chromatin remodeling. -
SMARCA2/4 Ligand
SMARCA2/4-ligand-5 is a selective ligand targeting the SMARCA2 and SMARCA4 proteins, functioning as a crucial component in the PROTAC SMARCA2/4 degrader-37. This compound demonstrates potent biological activity, achieving an IC50 of ≤0.1 μM, making it suitable for applications in targeted protein degradation studies. Research utilizing SMARCA2/4-ligand-5 contributes to understanding the roles of these chromatin remodelers in various biological processes and cancer biology. -
RAF Molecular Glue
NST-628 is a molecular glue targeting RAF within the MAPK signaling pathway. It disrupts RAF phosphorylation and MEK activation by preventing the formation of BRAF-CRAF and BRAF-ARAF heterodimers. NST-628 exhibits significant biological activity in inhibiting RAS- and RAF-driven cancers, particularly in tumors with mutant KRAS, NRAS, BRAF class II/III, and NF1 mutations. This compound is a valuable tool for research into targeted cancer therapies and understanding the RAS-MAPK pathway's role in oncogenesis. -
PROTAC BRAF-V600E Degrader
PROTAC BRAF-V600E Degrader-2 is a highly selective degrader targeting the BRAF-V600E mutant, with dissociation constants (Kd) of 14.4 nM and 9.5 nM for BRAF and BRAF-V600E, respectively. This compound effectively induces degradation of the BRAF-V600E kinase domain without impacting wild-type BRAF. Its potent biological activity makes it a valuable tool for research applications focused on melanoma cell growth inhibition and the study of BRAF-related signaling pathways. -
Ligand of BRAF
BRAF ligand-1 acts as a specific ligand for the BRAF protein, playing a crucial role in the regulation of cell signaling pathways associated with cell proliferation, survival, and differentiation. This compound is important for studying the BRAF signaling pathway and its implications in various cancers. Additionally, BRAF ligand-1 can be utilized in the synthesis of CST905, further enhancing its utility in biochemical research and drug discovery efforts targeting mutant BRAF. -
pan-KRAS PROTAC Degrader
MCB-36 is a VHL-recruiting pan-KRAS PROTAC degrader that targets various KRAS mutants, including G12D, G12C, G12V, and wild-type forms, with an exceptionally high binding affinity (Kd ≈ 1 pM). This compound effectively lowers p-ERK levels, promoting apoptosis in KRAS-driven cancer cells while showing minimal impact on HRAS and NRAS protein levels. MCB-36 is particularly useful for investigating colorectal and lung cancers, as it demonstrates efficacy against KRASG12C inhibitor-resistant tumors and aids in remodeling the tumor immune microenvironment. -
PROTAC Linkers
Fmoc-NH-PEG5-CH2COOH is a cleavable linker specifically designed for use in antibody-drug conjugates (ADCs) and as a PEG-based link in the synthesis of PROTACs. This compound facilitates the efficient conjugation of therapeutic agents to antibodies, enhancing targeted delivery. Its unique structure allows for controlled release, making it valuable in the development of innovative therapeutic strategies in drug discovery and bioconjugation research. -
ADC/PROTAC Linker
DBCO-NHCO-PEG4-NH-Boc is a versatile PROTAC linker featuring a cleavable structure designed for the synthesis of PROTACs and antibody-drug conjugates (ADCs). This compound utilizes a DBCO moiety, enabling efficient strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. Its PEG4 spacer enhances solubility and stability, making it suitable for various biological applications in drug development and therapeutic research. -
ADC/PROTAC Linker
DBCO-NHCO-PEG4-amine is a PEG-based linker designed for use in antibody-drug conjugates (ADCs) and PROTACs. This cleavable linker facilitates the conjugation of payloads such as MMAE to antibodies, enhancing targeted delivery to cancer cells. It has demonstrated compelling biological activities, with EC50 values of 280 nM and 22 nM for DBCO-VCpAB MMAE and DBCO-TRX MMAE, respectively, in SKBR3 cells, making it a valuable tool for researchers investigating targeted therapies. -
ADC/PROTAC Linker
Tr-PEG3-OH is a non-cleavable linker comprised of a three-unit polyethylene glycol (PEG) chain, designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound enhances the solubility and stability of ADCs, facilitating targeted delivery of cytotoxic agents to specific cells. Its applications extend to PROTAC (proteolysis-targeting chimera) technology, enabling the development of innovative therapies that harness targeted protein degradation. -
ADC/PROTAC Linker
Propargyl-PEG7-acid is a PEG-based linker designed for use in antibody-drug conjugates (ADCs) and proteolysis-targeting chimeras (PROTACs). It features a propargylic group that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc), enabling effective conjugation to azide-containing molecules. This compound serves as a cleavable linker, providing versatility in drug delivery systems and targeted therapy research. Propargyl-PEG7-acid is essential for studies focusing on the development of innovative therapeutic modalities through advanced chemical synthesis techniques. -
PROTAC Linkers
DBCO-N-bis(PEG4-NHS ester) is a bifunctional polyethylene glycol (PEG) linker featuring two NHS ester groups and a dibenzocyclooctyne (DBCO) moiety. This reagent facilitates protein modification and labeling, enhancing bioconjugation applications. As a click chemistry tool, DBCO-N-bis(PEG4-NHS ester) enables efficient strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, making it valuable for constructing PROTAC molecules and other bioorthogonal conjugates in various biochemical research settings. -
ADC/PROTAC Linker
Azido-PEG4-Val-Cit-PAB-OH is a cleavable polyethylene glycol (PEG) linker designed for use in antibody-drug conjugates (ADCs) and proteolysis-targeting chimeras (PROTACs). This compound features an azide group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, as well as strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN moieties. Its versatility as a click chemistry reagent supports diverse applications in chemical biology and drug development. -
PROTAC Linkers
m-PEG11-acid is a non-cleavable linker composed of 11 ethylene glycol units, functioning as a versatile agent in the synthesis of antibody-drug conjugates (ADCs) and PROTACs. This polyethylene glycol (PEG)-based linker enhances the solubility and pharmacokinetics of the conjugates while facilitating targeted degradation of proteins in research applications. m-PEG11-acid is crucial for investigating the mechanisms of protein regulation and therapeutic strategies in drug discovery. -
ADC/PROTAC Linker
m-PEG4-MS is a polyethylene glycol (PEG)-based linker designed for use in the synthesis of PROTACs and antibody-drug conjugates (ADCs). This cleavable linker facilitates the precise delivery of therapeutic agents, enhancing the stability and efficacy of the resulting compounds. Its application in PROTAC development and ADC formulation supports research into targeted protein degradation and innovative cancer therapies. -
ADC/PROTAC Linker
m-PEG7-Amine is a polyethylene glycol (PEG)-based linker designed for use in PROTAC (Proteolysis Targeting Chimeras) and antibody-drug conjugate (ADC) synthesis. This cleavable linker facilitates the targeted degradation of specific proteins, enhancing the efficacy of PROTACs. Its versatile application makes it an essential component in developing therapeutic modalities aimed at selective protein modulation and cancer treatment. -
PROTAC Linkers
m-PEG10-alcohol is a non-cleavable linker comprised of a decaethylene glycol unit, primarily used in the design of antibody-drug conjugates (ADCs). This PEG-based compound serves as a versatile PROTAC linker, facilitating the development of proteolysis-targeting chimeras. Its structure enhances solubility and stability, making it suitable for various chemical biology applications, including targeted protein degradation studies. -
PROTAC Linkers
(2R,4R)-4-Hydroxypyrrolidine-2-carboxylic acid hydrochloride functions as a non-cleavable linker in the development of antibody-drug conjugates (ADCs). Furthermore, it serves as an alkyl chain-based PROTAC linker, facilitating the synthesis of PROTACs. This compound plays a crucial role in advancing targeted protein degradation research, contributing to the exploration of innovative therapeutic strategies. -
PROTAC Linker
PC Alkyne-PEG4-NHS ester is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). Functioning as a PROTAC linker, this reagent features an alkyne group and participates in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions. Its unique structure enhances the specificity and efficiency of conjugating azide-containing molecules, making it valuable for various chemical biology applications, including targeted drug delivery and proteolysis targeting chimera (PROTAC) development. -
PROTAC Linker
TCO-PEG4-DBCO is a versatile PROTAC linker known for its ability to facilitate the synthesis of proteolysis-targeting chimeras (PROTACs). This compound features a DBCO moiety that enables strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing compounds, while the TCO component allows for inverse electron demand Diels-Alder (iEDDA) reactions with tetrazine derivatives. TCO-PEG4-DBCO finds applications in the development of antibody-drug conjugates (ADCs), enhancing the precision and efficacy of targeted therapeutics. Its unique chemical properties make it a valuable tool for researchers in chemical biology and drug development. -
ADC/PROTAC Linker
Propargyl-PEG8-bromide is a PEG-based linker designed for use in antibody-drug conjugates (ADCs) and PROTAC synthesis. This non-cleavable linker includes an alkyne group, enabling its application in click chemistry through copper-catalyzed azide-alkyne cycloaddition (CuAAc). Its versatility makes it a valuable tool for researchers in the development of targeted therapeutics and for probing protein degradation mechanisms. -
PROTAC Linkers
m-PEG10-acid is a polyethylene glycol (PEG) linker designed for use in the synthesis of antibody-drug conjugates (ADCs) and PROTACs (Proteolysis Targeting Chimeras). This non-cleavable 10-unit PEG linker enhances solubility and stability, facilitating effective delivery of therapeutic agents to targeted cells. The compound is instrumental in chemical biology applications, aiding in the development of novel targeted therapies and research into protein degradation mechanisms. -
PROTAC Linkers
N-Bromoacetyl-β-alanine is a versatile PROTAC linker that functions through targeted protein degradation pathways. This compound facilitates the synthesis of PROTACs, enabling the development of novel therapeutic strategies. Additionally, N-Bromoacetyl-β-alanine serves as a cleavable linker for antibody-drug conjugates (ADCs), enhancing the delivery of cytotoxic agents to specific cancer cells. Its utility in these applications makes it a valuable tool in chemical biology research. -
PROTAC Linker
β-D-tetraacetylgalactopyranoside-PEG1-N3 serves as a cleavable linker in PROTAC (proteolysis-targeting chimera) research, facilitating the synthesis of antibody-drug conjugates (ADCs). This compound features an azide group that allows for click chemistry applications, including copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules. Additionally, it is capable of undergoing strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with partners containing DBCO or BCN moieties, making it a versatile tool for bioconjugation and targeted drug delivery studies. -
ADC/PROTAC Linker
m-PEG8-MS is a polyethylene glycol (PEG)-based linker designed for use in antibody-drug conjugates (ADCs) and proteolysis-targeting chimeras (PROTACs). This cleavable linker facilitates the effective synthesis of ADCs, enhancing drug delivery specificity and potency. Its versatile applications in chemical biology allow for targeted degradation of selected proteins, making it a valuable tool in therapeutic development and research. -
ADC/PROTAC Linker
Propargyl-PEG1-SS-PEG1-C2-Boc is a versatile alkyl/ether-based linker with applications in PROTAC and antibody-drug conjugate (ADC) synthesis. This cleavable linker features an alkyne group, enabling its use in click chemistry via copper-catalyzed azide-alkyne cycloaddition (CuAAc). Propargyl-PEG1-SS-PEG1-C2-Boc is instrumental in the development of targeted therapeutic strategies, making it valuable for researchers in drug design and bioconjugation studies. -
PROTAC Linker
Tr-PEG8-OH is a non-cleavable linker composed of an 8 unit polyethylene glycol (PEG) chain, primarily utilized in the synthesis of PROTACs (proteolysis-targeting chimeras) and antibody-drug conjugates (ADCs). This PEG-based linker facilitates the development of optimized bioconjugates, enhancing their pharmacokinetic profiles and therapeutic efficacy. Tr-PEG8-OH is particularly valuable for research applications focusing on targeted protein degradation and drug delivery systems. -
ADC/PROTAC Linker
Propargyl-PEG4-thiol is a PEG-based linker specifically designed for use in the synthesis of PROTACs and non-cleavable antibody-drug conjugates (ADCs). This compound features an alkyne functional group that participates in copper-catalyzed azide-alkyne cycloaddition (CuAAc), facilitating precise conjugation with azide-containing molecules. Propargyl-PEG4-thiol is essential for advancing research in targeted protein degradation and therapeutic antibody development. -
ADC/PROTAC Linker
m-PEG7-MS is a polyethylene glycol (PEG)-based linker designed for use in the synthesis of PROTACs and antibody-drug conjugates (ADCs). This cleavable linker facilitates the development of targeted therapeutics by enabling controlled release of active compounds. Its versatile application supports research in targeted protein degradation and drug delivery systems, making it an essential reagent for advancing science in cancer therapy and other diseases. -
ADC/PROTAC Linker
DBCO-NHCO-PEG4-NHS ester is a versatile linker designed for use in the synthesis of PROTACs and antibody-drug conjugates (ADCs). This PEG/alkyl/ether-based compound features a DBCO moiety that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. Its cleavable nature enhances the functionality and targeting capabilities of therapeutic agents, making it essential for researchers involved in drug development and bioconjugation applications. -
ADC/PROTAC Linker
N-Boc-N-bis(PEG4-OH) is a PEG-based linker designed for use in PROTAC (proteolysis-targeting chimera) synthesis. This cleavable linker also serves as a versatile component for the development of antibody-drug conjugates (ADCs). Due to its unique structure, it facilitates targeted drug delivery and enhances the efficacy of therapeutic agents in various biological applications. -
PROTAC Linkers
Bis-PEG7-acid is a polyethylene glycol (PEG) based linker specifically designed for use in the synthesis of PROTACs (proteolysis-targeting chimeras). This compound enhances the solubility and stability of the PROTAC molecules, facilitating targeted protein degradation. Its application in chemical biology supports research focused on developing novel therapeutics through targeted ubiquitination pathways. -
ADC/PROTAC Linker
Propargyl-PEG9-bromide is a PEG-based linker utilized in the synthesis of PROTACs and antibody-drug conjugates (ADCs). This non-cleavable linker facilitates the targeted delivery of therapeutics through its unique click chemistry capabilities, featuring an alkyne group suitable for copper-catalyzed azide-alkyne cycloaddition (CuAAc). Its applications extend to enhancing drug efficacy and specificity in chemical biology and therapeutic development. -
PROTAC Linkers
m-PEG4-Boc is a cleavable polyethylene glycol (PEG) linker with four ethylene glycol units, designed for use in the synthesis of antibody-drug conjugates (ADCs) and Proteolysis Targeting Chimeras (PROTACs). This versatile linker facilitates the development of ADCs by enabling site-specific conjugation, while also serving as a crucial component in PROTAC design for targeted protein degradation. Its functional properties contribute to the effectiveness and stability of various bioconjugates in chemical biology research. -
PROTAC linker
Boc-gly-PEG3-endo-BCN is a cleavable PEG-based linker designed for targeted protein degradation applications through PROTAC technology. Its biocompatible structure facilitates the synthesis of antibody-drug conjugates (ADCs) by serving as a versatile linker. The presence of a bicyclo[6.1.0]nonyne (BCN) group allows for efficient strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with azide-containing molecules, making it a valuable reagent for click chemistry in biological research. -
ADC/PROTAC Linker
m-PEG5-MS is a PEG-based linker designed for antibody-drug conjugates (ADCs) and proteolysis-targeting chimeras (PROTACs). This cleavable linker facilitates the synthesis of PROTACs, enabling targeted degradation of specific proteins. Its key applications include drug development and cellular regulation studies, making it a versatile tool in therapeutic research and protein modulation.
